• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 4:35:17 PM ET
    $KIN
    Major Pharmaceuticals
    Health Care
    Get the next $KIN alert in real time by email
    SC 13G/A 1 kindredbiosc_13gam9dec312020.htm SC 13G/A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 9)*

     

     

    KINDRED BIOSCIENCES, INC.

    (Name of Issuer)

     

    Common Stock, PAR VALUE $0.0001 per share

    (Title of Class of Securities)

     

    494577109

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

     

    [   ] Rule 13d-1(b)

    [X] Rule 13d-1(c)

    [   ] Rule 13d-1(d)

      

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     
     

     

    CUSIP No.  494577109
    (1) Names of Reporting Persons
      Park West Asset Management LLC  
    (2) Check the Appropriate Box if a Member of a Group (a) [    ]  
      (b) [    ]  
         
    (3) SEC Use Only
    (4) Citizenship or Place of Organization
      Delaware  
    Number of Shares Beneficially Owned By Each Reporting Person With
      (5) Sole Voting Power: 0    
      (6) Shared Voting Power: 6,628,757*  
      (7) Sole Dispositive Power: 0    
      (8) Shared Dispositive Power: 6,628,757*  
           
    (9) Aggregate Amount Beneficially Owned by Each Reporting Person
      6,628,757*  
    (10) Check if the Aggregate Amount  in Row (9) Excludes Certain Shares (See Instructions):
      [    ]  
    (11) Percent of Class Represented by Amount in Row (9)
      16.8%*  
    (12) Type of Reporting Person
      IA  
                   

    * See Item 4 for additional information.

      

     
     

     

    CUSIP No.  494577109
    (1) Names of Reporting Persons
      Park West Investors Master Fund, Limited  
    (2) Check the Appropriate Box if a Member of a Group (a) [    ]  
      (b) [    ]  
         
    (3) SEC Use Only
    (4) Citizenship or Place of Organization
      Cayman Islands  
    Number of Shares Beneficially Owned By Each Reporting Person With
      (5) Sole Voting Power: 0    
      (6) Shared Voting Power: 6,000,439*  
      (7) Sole Dispositive Power: 0    
      (8) Shared Dispositive Power: 6,000,439*  
           
    (9) Aggregate Amount Beneficially Owned by Each Reporting Person
      6,000,439*  
    (10) Check if the Aggregate Amount  in Row (9) Excludes Certain Shares (See Instructions):
      [    ]  
    (11) Percent of Class Represented by Amount in Row (9)
      15.2%*  
    (12) Type of Reporting Person
      CO  
                   

    * See Item 4 for additional information.

     

     
     

     

    CUSIP No.  494577109
    (1) Names of Reporting Persons
      Park S. Park  
    (2) Check the Appropriate Box if a Member of a Group (a) [    ]  
      (b) [    ]  
         
    (3) SEC Use Only
    (4) Citizenship or Place of Organization
      United States of America  
    Number of Shares Beneficially Owned By Each Reporting Person With
      (5) Sole Voting Power: 0    
      (6) Shared Voting Power: 6,628,757*  
      (7) Sole Dispositive Power: 0    
      (8) Shared Dispositive Power: 6,628,757*   
           
    (9) Aggregate Amount Beneficially Owned by Each Reporting Person
      6,628,757*  
    (10) Check if the Aggregate Amount  in Row (9) Excludes Certain Shares (See Instructions):
      [    ]  
    (11) Percent of Class Represented by Amount in Row (9)
      16.8%*  
    (12) Type of Reporting Person
      IN  
                   

    * See Item 4 for additional information.

     

     
     

     


    Item 1(a).  Name Of Issuer:  Kindred Biosciences, Inc. (the “Company”)
       
    Item 1(b).  Address of Issuer’s Principal Executive Offices:
     

    1555 Bayshore Highway, Suite 200

    Burlingame, California 94010

     

    Item 2(a).  Name of Person Filing:
      This report on Schedule 13G (this “Schedule 13G”) is being jointly filed by (i) Park West Asset Management LLC, a Delaware limited liability company (“PWAM”), (ii) Park West Investors Master Fund, Limited, a Cayman Islands exempted company (“PWIMF”) and (iii) Peter S. Park (“Mr. Park” and, collectively with PWAM and PWIMF, the “Reporting Persons”).  
    Item 2(b).  Address of Principal Business Office or, if None, Residence:
     

    The address for the Reporting Persons is:  900 Larkspur Landing Circle, Suite 165, Larkspur, California 94939.

     

    Item 2(c).  Citizenship:
     

    PWAM is organized under the laws of the State of Delaware. PWIMF is a Cayman Islands exempted company. Mr. Park is a citizen of the United States.

     

    Item 2(d).  Title of Class of Securities:
      Common Stock, par value $0.0001 per share (“Common Stock”).
    Item 2(e).  CUSIP No.:
      494577109

      

    Item 3.  If This Statement Is Filed Pursuant to Rules 13d-1(b) or 13d-2(b) or (c), Check Whether the Person Filing is a:  
          Not Applicable.  
         
     
     

     

    Item 4.  Ownership:  
     

    As reported in the cover pages to this report, the ownership information with respect to each of PWAM and Mr. Park is as follows:

     

       
      (a)     Amount Beneficially Owned: 6,628,757*    
      (b)    Percent of Class: 16.8%*    
      (c)     Number of Shares as to which such person has:      
      (i)     Sole power to vote or to direct the vote: 0    
      (ii)    Shared power to vote or to direct the vote: 6,628,757*  
      (iii)   Sole power to dispose or to direct the disposition of: 0    
      (iv)   Shared power to dispose or to direct the disposition of: 6,628,757*   
           
     

    As reported in the cover pages to this report, the ownership information with respect to PWIMF is as follows:

     

       
      (a)     Amount Beneficially Owned: 6,000,439*    
      (b)     Percent of Class: 15.2%*    
      (c)     Number of Shares as to which such person has:      
      (i)     Sole power to vote or to direct the vote: 0    
      (ii)    Shared power to vote or to direct the vote: 6,000,439*   
      (iii)   Sole power to dispose or to direct the disposition of: 0     
      (iv)   Shared power to dispose or to direct the disposition of: 6,000,439*   
               

     

    * PWAM is the investment manager to PWIMF and Park West Partners International, Limited, a Cayman Islands exempted company (collectively, the “PW Funds”). Mr. Park, through one or more affiliated entities, is the controlling manager of PWAM. As of December 31, 2020, PWAM and Mr. Park may be deemed to beneficially own 6,628,757 shares of Common Stock held in the aggregate by the PW Funds.

    The reported beneficial ownership percentage is based upon approximately 39,448,813 shares of Common Stock issued and outstanding as of November 5, 2020, based on information reported by the Company in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2020.

     
     

     

    Item 5.  Ownership of Five Percent or Less of a Class:
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  [    ]
    Item 6.  Ownership of More Than Five Percent on Behalf of Another Person:
      Not Applicable.
    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
      Not Applicable.
    Item 8.  Identification and Classification of Members of the Group:
      Not Applicable.
    Item 9.  Notice of Dissolution of Group:
      Not Applicable.
    Item 10.  Certification:
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     
     
     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 16, 2021  
         
      PARK WEST ASSET MANAGEMENT LLC  
         
         
      By: /s/ Grace Jimenez  
      Name: Grace Jimenez  
      Title: Chief Financial Officer  

     

         
         
      PARK WEST INVESTORS MASTER FUND, LIMITED  
           
      By: Park West Asset Management LLC, its Investment Manager  

     

           
      By: /s/ Grace Jimenez  
      Name: Grace Jimenez  
      Title: Chief Financial Officer  
         

     

          /s/ Peter S. Park  
          Peter S. Park  
             
             

     

    Attention: Intentional misstatements or omissions of fact constitute

    Federal criminal violations (See 18 U.S.C. 1001)

     

     

     

     

     

     

     

     

     
     

    Exhibit Index

     

    Exhibit

     

    1.     Joint Filing Agreement, dated as of December 19, 2016, by and among Park West Asset Management LLC, Peter S. Park, and Park West Investors Master Fund, Limited (incorporated by reference to Exhibit A to Amendment No. 2 to Schedule 13G, filed with the Securities and Exchange Commission on December 19, 2016).

     

     

     

     

     

    Get the next $KIN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KIN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KIN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TCW Special Purpose Acquisition Corp. Appoints Nanxi Liu to Board of Directors

      TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to the Company's Board of Directors. Since April 2021, Ms. Liu has served on the TCW Special Purpose Acquisition Corporation's Advisory Board. She is the Co-Founder and Co-CEO of Blaze Technology, a no-code platform that enables teams to build web applications and internal tools. Ms. Liu co-founded and served as CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, until it was acquired in 2021. She previously co-founded Nanoly Bioscience, a venture-backed biotech company that develops po

      10/24/22 9:00:00 AM ET
      $ELAN
      $PRTS
      $TSPQ
      $KIN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Auto & Home Supply Stores
      Consumer Discretionary
    • Elanco Announces Agreement to Acquire Kindred Biosciences

      Bolt-on Acquisition Accelerates Elanco's Expansion in Pet Health Elanco to host conference call for investment community at 8:00 am Eastern Time    Elanco will acquire all outstanding stock of Kindred Biosciences at a price of $9.25 per share, or approximately $440 million, a premium of 52% based on the 30-day average. Transaction brings three potential blockbusters in the development phase, complements existing pipeline, and augments monoclonal antibody R&D capabilities. Increasing Investor Day revenue from innovation expectation by $100 million, to $600 million to $700 million by 2025, with significant opportunity beyond the period. Differentiated, disruptive portfolio in ato

      6/16/21 6:30:00 AM ET
      $KIN
      $ELAN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody for the Prevention of Deaths in Dogs Infected by Parvovirus

      SAN FRANCISCO, June 2, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study of KIND-030 in dogs infected by parvovirus. The primary endpoint was survival and the results showed 100% survival in the treated group versus 43% survival in the placebo group. KIND-030, a monoclonal antibody targeting canine parvovirus (CPV), is partnered with Elanco Animal Health (NYSE:ELAN). In this randomized, blinded, placebo-controlled study, KIND

      6/2/21 8:31:00 AM ET
      $KIN
      $ELAN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $KIN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kindred Biosciences downgraded by Lake Street with a new price target

      Lake Street downgraded Kindred Biosciences from Buy to Hold and set a new price target of $9.25 from $12.00 previously

      6/17/21 11:33:29 AM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • Kindred Biosciences downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Kindred Biosciences from Buy to Neutral and set a new price target of $9.25 from $9.00 previously

      6/17/21 6:07:16 AM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • Kindred Biosciences downgraded by Aegis Capital with a new price target

      Aegis Capital downgraded Kindred Biosciences from Buy to Hold and set a new price target of $9.25 from $16.00 previously

      6/16/21 9:21:39 AM ET
      $KIN
      Major Pharmaceuticals
      Health Care

    $KIN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Park West Asset Management Llc

      4 - Kindred Biosciences, Inc. (0001561743) (Issuer)

      9/13/21 4:30:38 PM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Chin Richard returned $15,884,757 worth of Common Stock to the company (1,717,271 units at $9.25), closing all direct ownership in the company

      4 - Kindred Biosciences, Inc. (0001561743) (Issuer)

      8/30/21 9:46:23 PM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Wee Wendy returned $727,170 worth of Common Stock to the company (78,613 units at $9.25), closing all direct ownership in the company

      4 - Kindred Biosciences, Inc. (0001561743) (Issuer)

      8/30/21 6:08:02 PM ET
      $KIN
      Major Pharmaceuticals
      Health Care

    $KIN
    Leadership Updates

    Live Leadership Updates

    See more
    • TCW Special Purpose Acquisition Corp. Appoints Nanxi Liu to Board of Directors

      TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to the Company's Board of Directors. Since April 2021, Ms. Liu has served on the TCW Special Purpose Acquisition Corporation's Advisory Board. She is the Co-Founder and Co-CEO of Blaze Technology, a no-code platform that enables teams to build web applications and internal tools. Ms. Liu co-founded and served as CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, until it was acquired in 2021. She previously co-founded Nanoly Bioscience, a venture-backed biotech company that develops po

      10/24/22 9:00:00 AM ET
      $ELAN
      $PRTS
      $TSPQ
      $KIN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Auto & Home Supply Stores
      Consumer Discretionary
    • TCW Special Purpose Acquisition Corp. Announces Appointment of Nanxi Liu to Advisory Board

      TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to its Advisory Board, effective April 26, 2021. Ms. Liu is Co-Founder and CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, and was named one of Forbes 30 Under 30 and Fortune's 10 Most Promising Women Entrepreneurs. She also co-founded Nanoly Bioscience, a venture-backed biotech company that develops polymers that eliminate the need of refrigeration for vaccines and therapeutics. Ms. Liu serves on the Board of Directors of CarParts.com (NASDAQ:PRTS), a leading online provider of aut

      4/26/21 8:30:00 AM ET
      $PRTS
      $KIN
      Auto & Home Supply Stores
      Consumer Discretionary
      Major Pharmaceuticals
      Health Care

    $KIN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Kindred Biosciences, Inc. (Amendment)

      SC 13G/A - Kindred Biosciences, Inc. (0001561743) (Subject)

      9/13/21 4:30:56 PM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Kindred Biosciences, Inc. (Amendment)

      SC 13D/A - Kindred Biosciences, Inc. (0001561743) (Subject)

      8/31/21 4:00:27 PM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Kindred Biosciences, Inc. (Amendment)

      SC 13D/A - Kindred Biosciences, Inc. (0001561743) (Subject)

      8/5/21 4:24:14 PM ET
      $KIN
      Major Pharmaceuticals
      Health Care

    $KIN
    SEC Filings

    See more
    • SEC Form 15-12B filed by Kindred Biosciences, Inc.

      15-12B - Kindred Biosciences, Inc. (0001561743) (Filer)

      9/7/21 6:09:47 AM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Kindred Biosciences, Inc.

      EFFECT - Kindred Biosciences, Inc. (0001561743) (Filer)

      9/2/21 12:15:28 AM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Kindred Biosciences, Inc.

      S-8 POS - Kindred Biosciences, Inc. (0001561743) (Filer)

      8/30/21 9:21:56 AM ET
      $KIN
      Major Pharmaceuticals
      Health Care